Clinical and Translational

Better Knowledge for Better Care with QIAGEN and N-of-One: Precision medicine for any cancer assay on any platform

629 views
May 29, 2019
For NGS cancer testing, keeping pace with new discoveries is a serious bottleneck. Valuable information can go undetected due to inadequate mining and interpretation mechanisms. These are called "knowledge blind spots" and can have significant clinical consequences. QIAGEN is the world leader in aggregating genetic disease knowledge resources. For the past 20 years, we have partnered with clinical testing labs throughout the world to manually curate genetic evidence across all human genes (23,000). N-of-One’s approach combines expert curation, the insights of oncology experts, and a proprietary technology and knowledgebase, MarkerMine™, to provide curated, high-quality, and actionable clinical interpretation of molecular tests. Join us for an informative webinar about both clinical interpretation solutions.

Interested in learning more?

Click here


Speakers: Dan Richards, Ph.D., Vice President of Biomedical Informatics at QIAGEN Sheryl Elkin, Ph.D., Chief Scientific Officer of N-of-One, Inc.Less

Related videos

Clinical and Translational

Accurate and efficient interpretation with QCI Precision Insights

152 views March 20, 2020

As next-generation DNA sequencing technology continues to evolve and become...

Clinical and Translational

QCI Interpret One: Oncology variant interpretation just got more precise

168 views June 12, 2020

Competing to offer a comprehensive genomic profiling service for solid or...

Clinical and Translational

How to reduce your test turnaround for large panels in molecular oncology

174 views December 31, 2019

Speaker: Sheryl Elkin, CSO, N-of-One.a QIAGEN Company Interested in learning...

Clinical and Translational

LeukoVantage: A Quest/Qiagen Partnership Providing Clinical Insights Into Myeloid Malignancies

146 views December 09, 2019

The integration of next-generation sequencing (NGS) into the diagnostic...